Stock Price Quote

NECTAR LIFESCIENCES LTD.

NSE : NECLIFEBSE : 532649ISIN CODE : INE023H01027Industry : Pharmaceuticals & DrugsHouse : Private
BSE10.97-0.04 (-0.36 %)
PREV CLOSE ( ) 11.01
OPEN PRICE ( ) 11.14
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 130957
TODAY'S LOW / HIGH ( )10.85 11.14
52 WK LOW / HIGH ( )10.89 28.27
NSE10.95-0.14 (-1.26 %)
PREV CLOSE( ) 11.09
OPEN PRICE ( ) 11.09
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 10.95 (353)
VOLUME 368011
TODAY'S LOW / HIGH( ) 10.80 11.20
52 WK LOW / HIGH ( )10.86 28.25
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 27-06 1995
Management Info
Sanjiv Goyal - Chairman Sanjiv Goyal - Managing Director
Registered Office

Address Shop No. 5, S L Enclave,Behind Sohi H P Gas Agency,Barwala Road, Dera Bassi,
SAS Nagar Dist,
Punjab-140507

Phone 01762-534001 / 534002

Email sales@neclife.com

Website www.neclife.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Luxembourg

NEWS

13Mar Nectar Lifesciences informs about minu
Nectar Lifesciences has informed that the Minutes of the Ordinary and Sp..
07Mar Nectar Lifesciences informs about disc
Nectar Lifesciences has informed that this is with reference to letter n..
06Mar Nectar Lifesciences acquires entire st
Nectar Lifesciences has acquired entire paid-up equity share capital in..
04Mar Nectar Lifesciences jumps on getting n
Nectar Lifesciences is currently trading at Rs. 11.84, up by 0.21 points..
02Mar Nectar Lifesciences informs about outc
Nectar Lifesciences has informed that the board of directors of the comp..

Financials

in Millions
QTR Dec 25 ANNUAL 25
Net Profit142.69-1136.81
Gross Profit 566 -1615.34
Operating Profit -12.64-245.669999999998
Net Sales 016730.75

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Acutaas Chemicals (BSE)
peergroup  2305.90 (6.60%)
M.Cap ( in Cr)18878.66
Astrazeneca Pharma I (BSE)
peergroup  8445.30 (1.04%)
M.Cap ( in Cr)21113.25
Ajanta Pharma (BSE)
peergroup  3020.95 (2.33%)
M.Cap ( in Cr)37742.43
Emcure Pharma (BSE)
peergroup  1509.85 (3.49%)
M.Cap ( in Cr)28625.18
Torrent Pharma (BSE)
peergroup  4305.95 (1.01%)
M.Cap ( in Cr)145732.91

Shareholding Pattern

NON-INSTITUTION 48.73%
PROMOTERS 44.91%
GOVERNMENT 0.02%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
FII 0%

About Nectar Lifesciences Ltd.

Nectar Lifesciences Ltd. was incorporated in the year 1995. Its today's share price is 10.97. Its current market capitalisation stands at Rs 213.1 Cr. In the latest quarter, company has reported Gross Sales of Rs. 19083.98 Cr and Total Income of Rs.16859.68 Cr. The company's management includes Surulichamy Senthil Kumar, Rupinder Tewari, Kuldip Kumar Bhasin, Indu Pal Kaur, Sanjiv Goyal, Sanjiv Goyal, Sanjaymohan Singh Rawat.

It is listed on the BSE with a BSE Code of 532649 , NSE with an NSE Symbol of NECLIFE and ISIN of INE023H01027. It's Registered office is at Shop No. 5, S L Enclave,Behind Sohi H P Gas Agency,Barwala Road, Dera BassiSAS Nagar Dist-140507, Punjab. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Ashwani K Gupta & Associates, Datta Singla & Co, Deepak Jindal & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.